Effectiveness of Intravenous Isoniazid and Ethambutol Administration in Patients with Tuberculosis Meningoencephalitis and HIV Infection
- Author:
Dmytro BUTOV
1
;
Yurii FESHCHENKO
;
Mykhailo KUZHKO
;
Mykola GUMENUIK
;
Kateryna YURKO
;
Alina GRYGOROVA
;
Anton TKACHENKO
;
Natalia NEKRASOVA
;
Tetiana TLUSTOVA
;
Vasyl KIKINCHUK
;
Alexandr PESHENKO
;
Tetiana BUTOVA
Author Information
- Publication Type:Original Article
- From:Tuberculosis and Respiratory Diseases 2020;83(1):96-103
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND:The aim of this study was to investigate the effectiveness of intravenous isoniazid (H) and ethambutol (E) administered in patients with new sputum positive drug-susceptible pulmonary tuberculosis (TB) with tuberculous meningoencephalitis (TM) and human immunodeficiency virus (HIV) co-infection in the intensive phase of treatment.
METHODS:Fifty-four patients with TB/TM and HIV co-infection were enrolled for this study. Group 1 comprised of 23 patients treated with E and H intravenously, while rifampicin and pyrazinamide were prescribed orally. Group 2 consisted of 31 patients treated with the first-line anti-TB drugs orally. The concentrations of H and E in blood serum were detected using a chromatographic method.
RESULTS:A significant improvement in the clinical symptoms and X-ray signs in patients treated intravenously with H and E was observed and compared to group 2. The sputum Mycobacterium tuberculosis positivity was observed during the second month of the treatment in 25.0% of patients from group 1 and 76.1% of the patients from the control group (p=0.003). In addition, nine patients (39.1%) died up to 6 months when H and E were prescribed intravenously compared with 22 (70.9%) in group 2 (p=0.023).
CONCLUSION:In TB/TM with HIV, the intravenous H and E treatment was more effective than oral H and E treatment at 2 months of intensive treatment in sputum conversion as well as in clinical improvement, accompanied by significantly higher mean serum concentrations. In addition, the mortality rate was lower in intravenous H and E treatment compared to oral treatment.
